The UK and US have agreed to a significant trade agreement that will guarantee no duties on British medicine products being sold in the US market.
Agreement Details of the Accord
In exchange for the tariff guarantee, the UK has committed to increase spending on drugs through the NHS. This move guarantees that import taxes on these crucial products will stay at zero for a duration of three years.
This agreement is in response to earlier warnings to hike tariffs on branded drug imports, with increases discussed reaching 100%.
"This agreement with the UK strengthens the global environment for new treatments and introduces long-overdue equity to U.S.–U.K. pharmaceutical trade," an announcement said.
Trade Impact
Drugs are one of the the United Kingdom's biggest goods shipped to the US, which is by far the biggest buyer for major UK drugmakers.
Trade data show that in the year prior to last September, the UK shipped medicines totaling £11.1bn to the US. This value represented 17.4% of British export trade in that period.
"This agreement protects jobs, boosts investment and facilitates the UK to establish itself as a worldwide center for medical research," a minister commented.
Detailed UK Commitments
The agreement entails several specific pledges from the British government:
- Higher Cost Ceiling: The UK will raise the price threshold at which it considers new treatments to be unaffordable by twenty-five percent.
- Higher Drug Budget: There is a goal to increase overall health service expenditure on drugs from 0.3 percent of the national economy to 0.6 percent over the coming ten years.
- Payback Limit: The sum manufacturers must pay back to the NHS to stay within budget will be limited at 15%. Previously, refunds were more than 20%.
Broader Context
This agreement takes place against a long-running tension between the drug companies and the ministers over spending levels and NHS adoption.
These tensions were exacerbated by claims that American customers were charged a premium for the identical medicines than consumers in the other developed nations.
Over the last 18 months, several major manufacturing plans in the UK have been paused or cancelled, while major investments have been directed toward US facilities.
The Science Minister publicly accepted that the NHS had to spend more on drugs, noting that its spending on drugs had declined as a share of its overall budget over the previous ten-year period.
